LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

DexCom Inc

Geschlossen

BrancheGesundheitswesen

78.39 0.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

77.59

Max

79.09

Schlüsselkennzahlen

By Trading Economics

Einkommen

74M

180M

Verkäufe

121M

1.2B

KGV

Branchendurchschnitt

53.056

35.733

EPS

0.32

Gewinnspanne

15.539

Angestellte

10,200

EBITDA

90M

309M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+28.56% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

23. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5.6B

30B

Vorheriger Eröffnungskurs

77.81

Vorheriger Schlusskurs

78.39

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

DexCom Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juli 2025, 18:41 UTC

Akquisitionen, Fusionen, Übernahmen

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

25. Okt. 2024, 09:10 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

DexCom Inc Prognose

Kursziel

By TipRanks

28.56% Vorteil

12-Monats-Prognose

Durchschnitt 100.28 USD  28.56%

Hoch 112 USD

Tief 87 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für DexCom Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

22 ratings

18

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

71.66 / N/AUnterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Neutral Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat